
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7862372/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Post-Pulmonary Embolism Syndrome and Functional Outcomes after Acute Pulmonary Embolism. Seminars in Thrombosis and Hemostasis, 2023, 49, 848-860.	2.7	8
2	Home Treatment Compared to Initial Hospitalization in Normotensive Patients with Acute Pulmonary Embolism in the Netherlands: A Cost Analysis. Thrombosis and Haemostasis, 2022, 122, 427-433.	3.4	3
3	Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. Thrombosis and Haemostasis, 2022, 122, 857-866.	3.4	35
4	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. Thrombosis and Haemostasis, 2022, 122, 646-656.	3.4	25
5	Inter―and intraâ€individual concentrations of direct oral anticoagulants: The KIDOAC study. Journal of Thrombosis and Haemostasis, 2022, 20, 92-103.	3.8	19
6	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. European Heart Journal, 2022, 43, 183-189.	2.2	83
7	Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematology,the, 2022, 9, e73-e80.	4.6	114
8	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. Annals of Internal Medicine, 2022, 175, 29-35.	3.9	33
9	Prediction of chronic thromboembolic pulmonary hypertension with standardised evaluation of initial computed tomography pulmonary angiography performed for suspected acute pulmonary embolism. European Radiology, 2022, 32, 2178-2187.	4.5	18
10	Unequal prescription of anticoagulants among females and males with atrial fibrillation and similar stroke risk: Should we omit sex category from the CHA2DS2-VASc score?. Heart Rhythm, 2022, 19, 860-861.	0.7	1
11	Ruling out pulmonary embolism across different healthcare settings: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2022, 19, e1003905.	8.4	19
12	Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia. European Journal of Haematology, 2022, 108, 310-318.	2.2	0
13	Safety and Efficiency of Diagnostic Strategies for Ruling Out Pulmonary Embolism in Clinically Relevant Patient Subgroups. Annals of Internal Medicine, 2022, 175, 244-255.	3.9	27
14	Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. Clinical Research in Cardiology, 2022, 111, 560-573.	3.3	15
15	Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The CLORIAâ€AF Phase III Registry. Journal of the American Heart Association, 2022, 11, e023907.	3.7	12
16	Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry. Clinical Research in Cardiology, 2022, 111, 548-559.	3.3	12
17	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. European Journal of Cancer, 2022, 165, 136-145.	2.8	11
18	First do no harm. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12694.	2.3	2

#	Article	IF	CITATIONS
19	Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. Journal of Thrombosis and Haemostasis, 2022, 20, 1665-1673.	3.8	16
20	Determinants of label non-adherence to non-vitamin K oral anticoagulants in patients with newly diagnosed atrial fibrillation. European Heart Journal Open, 2022, 2, .	2.3	1
21	Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry. Clinical Research in Cardiology, 2022, 111, 1057-1068.	3.3	8
22	Diagnostic Management of Acute Pulmonary Embolism in COVID-19 and Other Special Patient Populations. Diagnostics, 2022, 12, 1350.	2.6	4
23	Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and Haemostasis, 2021, 121, 616-624.	3.4	55
24	Direct Oral Anticoagulants Are a Potential Alternative to Low-Molecular-Weight Heparin for Thromboprophylaxis in Trauma Patients Sustaining Lower Extremity Fractures. Journal of Surgical Research, 2021, 258, 324-331.	1.6	13
25	Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. Hellenic Journal of Cardiology, 2021, 62, 152-157.	1.0	2
26	Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score. Heart, 2021, 107, 549-555.	2.9	5
27	Computed Tomography Pulmonary Perfusion for Prediction of Short-Term Clinical Outcome in Acute Pulmonary Embolism. TH Open, 2021, 05, e66-e72.	1.4	2
28	The prognostic value of ECG-derived ventricular gradient in early adverse events in acute pulmonary embolism patients. Thrombosis Update, 2021, 2, 100033.	0.9	3
29	Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF. TH Open, 2021, 05, e35-e42.	1.4	1
30	Magnetic resonance thrombus imaging for the differentiation of chronic versus (sub)acute cerebral vein thrombosis: A case report. Thrombosis Update, 2021, 2, 100039.	0.9	1
31	Determinants and Management of the Post–Pulmonary Embolism Syndrome. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 299-307.	2.1	22
32	Prophylaxis and treatment of COVID-19 related venous thromboembolism. Postgraduate Medicine, 2021, 133, 27-35.	2.0	22
33	Risk of thrombotic complications in influenza versus COVIDâ€19 hospitalized patients. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 412-420.	2.3	47
34	Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. Thorax, 2021, 76, 1002-1009.	5.6	41
35	Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thrombosis Research, 2021, 199, 143-148.	1.7	98
36	Computed tomography pulmonary perfusion imaging and 3-months clinical outcomes after acute pulmonary embolism. Thrombosis Research, 2021, 199, 32-34.	1.7	3

#	Article	IF	CITATIONS
37	Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis. Blood Advances, 2021, 5, 1369-1378.	5.2	3
38	Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS ONE, 2021, 16, e0249524.	2.5	6
39	Coronavirus disease 2019 is associated with catheter-related thrombosis in critically ill patients: A multicenter case-control study. Thrombosis Research, 2021, 200, 87-90.	1.7	11
40	Diagnostic accuracy of four different D-dimer assays: A post-hoc analysis of the YEARS study. Thrombosis Research, 2021, 201, 18-22.	1.7	6
41	Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. Pharmacoepidemiology and Drug Safety, 2021, 30, 1027-1036.	1.9	4
42	Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer, 2021, 148, 371-381.	2.8	38
43	Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis. Critical Care Medicine, 2021, 49, e1025-e1036.	0.9	33
44	Detection of upper extremity deep vein thrombosis by magnetic resonance non ontrast thrombus imaging. Journal of Thrombosis and Haemostasis, 2021, 19, 1973-1980.	3.8	5
45	Evolution of CT findings after anticoagulant treatment for acute pulmonary embolism in patients with and without an ultimate diagnosis of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 58, 2100699.	6.7	16
46	Challenges in the diagnostic approach of suspected pulmonary embolism in COVID-19 patients. Postgraduate Medicine, 2021, 133, 36-41.	2.0	12
47	Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program. IJC Heart and Vasculature, 2021, 34, 100763.	1.1	4
48	Toward a tailored diagnostic standard for future diagnostic studies in pulmonary embolism: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 1834-1835.	3.8	1
49	Pulmonary infarction in acute pulmonary embolism. Thrombosis Research, 2021, 202, 162-169.	1.7	34
50	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. Journal of Thrombosis and Haemostasis, 2021, 19, 2751-2759.	3.8	18
51	Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world. Journal of Arrhythmia, 2021, 37, 990-1006.	1.2	19
52	Ruling out Pulmonary Embolism in Patients with (Suspected) COVID-19—A Prospective Cohort Study. TH Open, 2021, 05, e387-e399.	1.4	7
53	Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis, 2021, 19, 1874-1882.	3.8	122
54	Identification of chronic thromboembolic pulmonary hypertension on CTPAs performed for diagnosing acute pulmonary embolism depending on level of expertise. European Journal of Internal Medicine, 2021, 93, 64-70.	2.2	15

#	Article	IF	CITATIONS
55	A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension. ERJ Open Research, 2021, 7, 00719-2020.	2.6	14
56	Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. European Heart Journal, 2021, 42, 3146-3157.	2.2	64
57	Antithrombotic Therapy for VTE Disease. Chest, 2021, 160, e545-e608.	0.8	357
58	Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. European Journal of Internal Medicine, 2021, 91, 75-80.	2.2	1
59	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. Journal of Thrombosis and Haemostasis, 2021, 19, 3008-3017.	3.8	10
60	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematology,the, 2021, 8, e627-e636.	4.6	11
61	Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE Syndrome. Thrombosis Research, 2021, 206, 66-75.	1.7	24
62	Why, Whom, and How to Screen for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism. Seminars in Thrombosis and Hemostasis, 2021, 47, 692-701.	2.7	10
63	Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation. JAMA - Journal of the American Medical Association, 2021, 326, 1277.	7.4	28
64	Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program. Medicina ClÃnica, 2021, , .	0.6	1
65	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. Haematologica, 2020, 105, 1436-1442.	3.5	19
66	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603.	2.2	2,426
67	Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry. American Journal of Cardiology, 2020, 125, 383-391.	1.6	19
68	Pulmonary vascular imaging characteristics after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2020, 39, 248-256.	0.6	16
69	Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists. Thrombosis Research, 2020, 196, 404-409.	1.7	0
70	Reasons for Hospitalization of Patients with Acute Pulmonary Embolism Based on the Hestia Decision Rule. Thrombosis and Haemostasis, 2020, 120, 1217-1220.	3.4	2
71	Lack of diagnostic utility of the ECG-derived ventricular gradient in patients with suspected acute pulmonary embolism. Journal of Electrocardiology, 2020, 61, 141-146.	0.9	2
72	Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1251-1261.	2,3	18

#	Article	IF	CITATIONS
73	Magnetic Resonance Thrombus Imaging to Differentiate Acute from Chronic Portal Vein Thrombosis. TH Open, 2020, 04, e224-e230.	1.4	6
74	Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry. IJC Heart and Vasculature, 2020, 31, 100666.	1.1	2
75	Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation. BMJ Open, 2020, 10, e036220.	1.9	7
76	How can we better predict pulmonary blood clots in patients hospitalised for COVID-19?. European Respiratory Journal, 2020, 56, 2003092.	6.7	1
77	Clinical Surveillance vs. Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE). BMJ Open, 2020, 10, e040151.	1.9	13
78	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 1128-1136.	3.4	93
79	Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program. European Journal of Internal Medicine, 2020, 80, 35-44.	2.2	9
80	Current practice patterns of outpatient management of acute pulmonary embolism: A post-hoc analysis of the YEARS study. Thrombosis Research, 2020, 193, 60-65.	1.7	7
81	Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thrombosis Research, 2020, 191, 148-150.	1.7	1,357
82	Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?. Thrombosis Research, 2020, 193, 86-89.	1.7	156
83	Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIAâ€AF registry. Journal of Arrhythmia, 2020, 36, 408-416.	1.2	11
84	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. Circulation, 2020, 142, 621-642.	1.6	232
85	Anticoagulant treatment and bleeding complications in patients with left ventricular assist devices. Expert Review of Cardiovascular Therapy, 2020, 18, 363-372.	1.5	22
86	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. New England Journal of Medicine, 2020, 382, 1599-1607.	27.0	658
87	Uncertain Value of Highâ€sensitive Troponin T for Selecting Patients With Acute Pulmonary Embolism for Outpatient Treatment by Hestia Criteria. Academic Emergency Medicine, 2020, 27, 1043-1046.	1.8	9
88	Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns. Journal of Thrombosis and Haemostasis, 2020, 18, 1390-1397.	3.8	12
89	Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. Journal of Clinical Medicine, 2020, 9, 1969.	2.4	11
90	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. Gerontology, 2020, 66, 447-459.	2.8	4

#	Article	IF	CITATIONS
91	Safety of using the combination of the Wells rule and Dâ€dimer test for excluding acute recurrent ipsilateral deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2020, 18, 2341-2348.	3.8	8
92	Characteristics and 2â€year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIAâ€AF. ESC Heart Failure, 2020, 7, 2679-2689.	3.1	7
93	Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice. TH Open, 2020, 04, e119-e126.	1.4	3
94	Anticoagulation practice patterns in COVIDâ€19: A global survey. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 969-983.	2.3	35
95	Effect of No Prehydration vs Sodium Bicarbonate Prehydration Prior to Contrast-Enhanced Computed Tomography in the Prevention of Postcontrast Acute Kidney Injury in Adults With Chronic Kidney Disease. JAMA Internal Medicine, 2020, 180, 533.	5.1	39
96	Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism. PLoS ONE, 2020, 15, e0232354.	2.5	9
97	Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research, 2020, 191, 145-147.	1.7	3,872
98	Diagnostic management of acute pulmonary embolism in special populations. Expert Review of Respiratory Medicine, 2020, 14, 729-736.	2.5	10
99	Current imaging modalities for diagnosing cerebral vein thrombosis – A critical review. Thrombosis Research, 2020, 189, 132-139.	1.7	35
100	Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale. Thrombosis Research, 2020, 190, 45-51.	1.7	44
101	Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. Blood, 2020, 135, 1377-1385.	1.4	39
102	How I assess and manage the risk of bleeding in patients treated for venous thromboembolism. Blood, 2020, 135, 724-734.	1.4	66
103	Clinical trial results – A closer look under the surface. European Journal of Internal Medicine, 2020, 75, 21-22.	2.2	1
104	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. European Heart Journal, 2020, 41, 1132-1140.	2.2	50
105	When I treat a patient with acute pulmonary embolism at home. Hematology American Society of Hematology Education Program, 2020, 2020, 190-194.	2.5	6
106	Differential effect of anticoagulant treatment on vascular morphology in patients with acute pulmonary embolism. European Heart Journal, 2020, 41, .	2.2	0
107	Accurate and efficient non-invasive strategy for early identification of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism (InShape II study). European Heart Journal, 2020, 41, .	2.2	0
108	Computed tomography pulmonary angiography <i>versus</i> ventilation-perfusion lung scanning for diagnosing pulmonary embolism during pregnancy: a systematic review and meta-analysis. Haematologica, 2019, 104, 176-188.	3.5	56

#	Article	IF	CITATIONS
109	Occurrence of Antithrombotic Related Adverse Events in Hospitalized Patients: Incidence and Clinical Context between 2008 and 2016. Journal of Clinical Medicine, 2019, 8, 839.	2.4	4
110	Duration of anticoagulant treatment for unprovoked deep-vein thrombosis – is prolonged long enough?. Haematologica, 2019, 104, 1300-1301.	3.5	0
111	Direct oral anticoagulants and obesity: one size fits all?. Lancet Haematology,the, 2019, 6, e341-e342.	4.6	0
112	Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. Europace, 2019, 22, 47-57.	1.7	10
113	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Respiratory Journal, 2019, 54, 1901647.	6.7	806
114	Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. PLoS ONE, 2019, 14, e0222658.	2.5	21
115	<p>When to withhold oral anticoagulation in atrial fibrillation – an overview of frequent clinical discussion topics</p> . Vascular Health and Risk Management, 2019, Volume 15, 399-408.	2.3	16
116	Comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'. British Journal of Cancer, 2019, 120, 472-472.	6.4	0
117	Chest X-Ray Not Routinely Indicated Prior to the YEARS Algorithm in the Diagnostic Management of Suspected Pulmonary Embolism. TH Open, 2019, 03, e22-e27.	1.4	4
118	The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. Clinical Cardiology, 2019, 42, 346-351.	1.8	9
119	Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism. New England Journal of Medicine, 2019, 380, 1139-1149.	27.0	200
120	Atrial fibrillation and cancer – An unexplored field in cardiovascular oncology. Blood Reviews, 2019, 35, 59-67.	5.7	64
121	Post-thrombotic syndrome: Short and long-term incidence and risk factors. Thrombosis Research, 2019, 177, 102-109.	1.7	19
122	Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identification of chronic thromboembolic pulmonary hypertension: results of the InShape III study. Journal of Heart and Lung Transplantation, 2019, 38, 731-738.	0.6	54
123	Diagnosing Recurrent DVT of the Leg by Two Different Non–Contrast-Enhanced Magnetic Resonance Direct Thrombus Imaging Techniques: A Pilot Study. TH Open, 2019, 03, e37-e44.	1.4	6
124	Validation and impact of a simplified clinical decision rule for diagnosing pulmonary embolism in primary care: design of the PECAN prospective diagnostic cohort management study. BMJ Open, 2019, 9, e031639.	1.9	8
125	How reliable is perioperative anticoagulant management? Determining guideline compliance and practice variation by a retrospective patient record review. BMJ Open, 2019, 9, e029879.	1.9	3
126	Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial. BMJ Open, 2019, 9, e032488.	1.9	12

#	Article	IF	CITATIONS
127	Home treatment of patients with cancer-associated venous thromboembolism – An evaluation of daily practice. Thrombosis Research, 2019, 184, 122-128.	1.7	11
128	Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program. American Heart Journal, 2019, 218, 123-127.	2.7	18
129	Performance of idarucizumab as antidote of dabigatran in daily clinical practice. Europace, 2019, 21, 414-420.	1.7	31
130	Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. Circulation, 2019, 139, 748-756.	1.6	36
131	Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism. Blood, 2019, 134, 2429-2429.	1.4	2
132	Magnetic Resonance Direct Thrombus Imaging (MRDTI) Can Distinguish Between Old and New Thrombosis in the Abdominal Aorta: a Case Report. European Journal of Case Reports in Internal Medicine, 2019, 7, 001351.	0.4	3
133	Clinical effects of antiplatelet drugs and statins on Dâ€dimer levels. European Journal of Clinical Investigation, 2018, 48, e12944.	3.4	18
134	Clinical outcome of patients with a vitamin K antagonistâ€associated bleeding treated with prothrombin complex concentrate. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 77-84.	2.3	6
135	Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. American Journal of Medicine, 2018, 131, 945-955.e3.	1.5	27
136	Diagnosing upper extremity deep vein thrombosis with non-contrast-enhanced Magnetic Resonance Direct Thrombus Imaging: A pilot study. Thrombosis Research, 2018, 163, 47-50.	1.7	14
137	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. Thrombosis Research, 2018, 163, 128-131.	1.7	4
138	Higher Adherence to Treatment With Lowâ€Molecularâ€Weightâ€Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancerâ€Associated Venous Thromboembolism. HemaSphere, 2018, 2, e19.	2.7	8
139	Strokeâ€prevention strategies in North American patients with atrial fibrillation: The GLORIAâ€AF registry program. Clinical Cardiology, 2018, 41, 744-751.	1.8	19
140	Diagnosis of recurrent venous thromboembolism. Thrombosis Research, 2018, 163, 229-235.	1.7	14
141	Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Clobal Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (CLORIA-AF) registry. American Heart Journal, 2018, 198, 55-63.	2.7	40
142	Diclofenac for reversal of right ventricular dysfunction in acute normotensive pulmonary embolism: A pilot study. Thrombosis Research, 2018, 162, 1-6.	1.7	5
143	Efficacy and safety outcomes of recanalisation procedures in patients with acute symptomatic pulmonary embolism: systematic review and network meta-analysis. Thorax, 2018, 73, 464-471.	5.6	33
144	Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints. Pharmacoepidemiology and Drug Safety, 2018, 27, 1371-1378.	1.9	1

#	Article	IF	CITATIONS
145	Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. European Respiratory Review, 2018, 27, 180094.	7.1	16
146	Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis. European Heart Journal, 2018, 39, 4186-4195.	2.2	55
147	Lower prevalence of subsegmental pulmonary embolism after application of the <scp>YEARS</scp> diagnostic algorithm. British Journal of Haematology, 2018, 183, 629-635.	2.5	20
148	Pulmonary embolism. Nature Reviews Disease Primers, 2018, 4, 18028.	30.5	208
149	Persistence to direct oral anticoagulants for acute venous thromboembolism. Thrombosis Research, 2018, 167, 135-141.	1.7	5
150	Sensitivity of a Simple Noninvasive Screening Algorithm for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism. TH Open, 2018, 02, e89-e95.	1.4	17
151	Management and treatment of deep vein thrombosis in special populations. Expert Review of Hematology, 2018, 11, 685-695.	2.2	20
152	Pharmacological properties of betrixaban. European Heart Journal Supplements, 2018, 20, E12-E15.	0.1	32
153	Antithrombotic therapy after mitral valve repair: VKA or aspirin?. Journal of Thrombosis and Thrombolysis, 2018, 46, 473-481.	2.1	19
154	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. Thrombosis and Haemostasis, 2018, 118, 1668-1678.	3.4	121
155	Novel Anticoagulant Treatment for Pulmonary Embolism with Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice. Seminars in Interventional Radiology, 2018, 35, 83-91.	0.8	4
156	Randomized trial of one-hour sodium bicarbonate vs standard periprocedural saline hydration in chronic kidney disease patients undergoing cardiovascular contrast procedures. PLoS ONE, 2018, 13, e0189372.	2.5	12
157	Safety and Efficiency of the YEARS Diagnostic Algorithm for Pregnant Patients with Clinically Suspected Acute Pulmonary Embolism —the Artemis Study. Blood, 2018, 132, 419-419.	1.4	0
158	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE ADâ"¢ study. Journal of Medical Economics, 2017, 20, 435-442.	2.1	7
159	To screen or not to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thrombosis Research, 2017, 151, 1-7.	1.7	45
160	The Changing Landscape for StrokeÂPrevention in AF. Journal of the American College of Cardiology, 2017, 69, 777-785.	2.8	244
161	Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. European Respiratory Journal, 2017, 49, 1601792.	6.7	339
162	Pitfalls in the diagnostic management of pulmonary embolism in pregnancy. Thrombosis Research, 2017, 151, S86-S91.	1.7	18

#	Article	IF	CITATIONS
163	Performance of the age-adjusted cut-off for D-dimer in patients with cancer and suspected pulmonary embolism. Thrombosis Research, 2017, 152, 49-51.	1.7	12
164	Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis. Thrombosis Research, 2017, 154, 64-72.	1.7	11
165	Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet, The, 2017, 390, 289-297.	13.7	357
166	Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort. Rheumatology, 2017, 56, 1676-1683.	1.9	50
167	Persistence With Dabigatran Therapy at 2ÂYears in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 1573-1583.	2.8	39
168	Management of incidental pulmonary embolism. European Respiratory Journal, 2017, 49, 1700275.	6.7	43
169	Therapeutic management of acute pulmonary embolism. Expert Review of Respiratory Medicine, 2017, 11, 641-648.	2.5	1
170	Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. American Journal of Medicine, 2017, 130, 135-145.	1.5	40
171	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. Thrombosis and Haemostasis, 2017, 117, 2425-2434.	3.4	9
172	Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. Thrombosis and Haemostasis, 2017, 117, 2163-2167.	3.4	3
173	Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry. Thrombosis and Haemostasis, 2017, 117, 2376-2388.	3.4	84
174	Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ: British Medical Journal, 2017, 356, j1065.	2.3	174
175	P1618Lower prevalence of isolated subsegmental pulmonary embolism in the YEARS diagnostic algorithm compared with the conventional algorithm for suspected pulmonary embolism. European Heart Journal, 2017, 38, .	2.2	0
176	Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability?. Thrombosis and Haemostasis, 2017, 117, 1622-1629.	3.4	17
177	Accuracy and reproducibility of CT right-to-left ventricular diameter measurement in patients with acute pulmonary embolism. PLoS ONE, 2017, 12, e0188862.	2.5	28
178	Wells Rule and <scp>d</scp> -Dimer Testing to Rule Out Pulmonary Embolism. Annals of Internal Medicine, 2016, 165, 253.	3.9	119
179	Efficacy and Safety of Outpatient Treatment Based on the Hestia Clinical Decision Rule with or without N-Terminal Pro–Brain Natriuretic Peptide Testing in Patients with Acute Pulmonary Embolism. A Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 998-1006.	5.6	107
180	Evaluation of the new simple and objective clinical decision rule "l-DVT―in patients with clinically suspected acute deep vein thrombosis. Thrombosis Research, 2016, 141, 112-118.	1.7	6

#	Article	IF	CITATIONS
181	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Critical Care, 2016, 20, 115.	5.8	40
182	Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. American Journal of Medicine, 2016, 129, S89-S96.	1.5	12
183	Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. American Journal of Emergency Medicine, 2016, 34, 46-51.	1.6	16
184	Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace, 2016, 18, 1308-1318.	1.7	54
185	Letter to the Editor. Journal of Intensive Care Medicine, 2016, 31, 70-71.	2.8	Ο
186	Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer. Chest, 2016, 149, 1245-1251.	0.8	38
187	Antithrombotic Therapy for VTE Disease. Chest, 2016, 149, 315-352.	0.8	4,060
188	Aortic Arch Stiffness Is Associated With Incipient Brain Injury in Patients With Hypertension. American Journal of Hypertension, 2016, 29, 705-712.	2.0	8
189	Accurate diagnosis of iliac vein thrombosis in pregnancy with magnetic resonance direct thrombus imaging (MRDTI). BMJ Case Reports, 2016, 2016, bcr2016218091.	0.5	8
190	Dabigatran Is Associated with a Significantly Lower Risk of Abnormal Uterine Bleeding Than Warfarin in Female Patients of Childbearing Age with Venous Thromboembolism. Blood, 2016, 128, 140-140.	1.4	8
191	Persistence with Dabigatran Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation: The Gloria-AF Registry. Blood, 2016, 128, 2616-2616.	1.4	12
192	The Performance of the Original and Simplified Wells Scores in Combination with Age-Adjusted D-Dimer Testing in the Diagnostic Management of Pulmonary Embolism. Blood, 2016, 128, 2569-2569.	1.4	0
193	Current challenges in diagnostic imaging of venous thromboembolism. Hematology American Society of Hematology Education Program, 2015, 2015, 202-209.	2.5	5
194	Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism. Haematologica, 2015, 100, 188-193.	3.5	16
195	Current challenges in diagnostic imaging of venous thromboembolism. Blood, 2015, 126, 2376-2382.	1.4	23
196	Performance of a diagnostic algorithm based on a prediction rule, D-dimer and CT-scan for pulmonary embolism in patients with previous venous thromboembolism. Thrombosis and Haemostasis, 2015, 113, 406-413.	3.4	19
197	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thrombosis and Haemostasis, 2015, 114, 198-205.	3.4	132
198	No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study. Pharmacological Research, 2015, 94, 1-8.	7.1	11

#	Article	IF	CITATIONS
199	Time-Dependent Effects of Aspirin on Blood Pressure and Morning Platelet Reactivity. Hypertension, 2015, 65, 743-750.	2.7	62
200	Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. American Journal of Medicine, 2015, 128, 1306-1313.e1.	1.5	135
201	Idarucizumab for Dabigatran Reversal. New England Journal of Medicine, 2015, 373, 511-520.	27.0	1,419
202	Patients With Atrial Fibrillation and a CHA2DS2-VASc Score of 1. Journal of the American College of Cardiology, 2015, 65, 1395-1397.	2.8	8
203	Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic) Tj ETQq1 1	0,784314 1.7	⊦rgBT /Overle
204	Imaging Tests for Suspected Deep Vein Thrombosis. JAMA Internal Medicine, 2015, 175, 1873.	5.1	0
205	Reliability of diagnosing incidental pulmonary embolism in cancer patients. Thrombosis Research, 2015, 136, 531-534.	1.7	22
206	Computerised clinical decision support for suspected PE: TableÂ1. Thorax, 2015, 70, 909-911.	5.6	22
207	External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thrombosis Research, 2015, 135, 796-801.	1.7	50
208	Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. European Respiratory Journal, 2015, 45, 201-210.	6.7	82
209	The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PLoS ONE, 2015, 10, e0122520.	2.5	69
210	Performance of the revised Geneva score in patients with a delayed suspicion of pulmonary embolism. European Respiratory Journal, 2014, 43, 1801-1804.	6.7	4
211	Age-Adjusted D-Dimer Cutoff Levels to Rule Out Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2014, 311, 1117.	7.4	680
212	Optimization of the diagnostic management of clinically suspected pulmonary embolism in hospitalized patients. British Journal of Haematology, 2014, 167, 681-686.	2.5	11
213	The Newer Anticoagulants in Thrombosis Control in Cancer Patients. Seminars in Oncology, 2014, 41, 339-345.	2.2	4
214	Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. American Heart Journal, 2014, 167, 329-334.	2.7	112
215	Dabigatran-related coagulopathy: when can we assume the effect has "worn off�. American Journal of Emergency Medicine, 2014, 32, 1433-1434.	1.6	1
216	The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Reviews, 2014, 28, 221-226.	5.7	296

#	Article	IF	CITATIONS
217	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	2.2	2,591
218	Advances in the diagnosis and management of acute pulmonary embolism. Thrombosis Research, 2014, 133, S10-S16.	1.7	15
219	Diagnostic outcome management study in patients with clinically suspected recurrent acute pulmonary embolism with a structured algorithm. Thrombosis Research, 2014, 133, 1039-1044.	1.7	30
220	Magnetic resonance direct thrombus imaging differentiates acute recurrent ipsilateral deep vein thrombosis from residual thrombosis. Blood, 2014, 124, 623-627.	1.4	81
221	Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease. PLoS ONE, 2014, 9, e94420.	2.5	35
222	Seeking optimal treatment for phlegmasia cerulea dolens. Thrombosis Research, 2013, 131, 372-373.	1.7	11
223	Impact of Delay in Clinical Presentation on the Diagnostic Management and Prognosis of Patients with Suspected Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1369-1373.	5.6	37
224	Outpatient <i>versus</i> inpatient treatment in patients with pulmonary embolism: a meta-analysis. European Respiratory Journal, 2013, 42, 134-144.	6.7	152
225	How I diagnose acute pulmonary embolism. Blood, 2013, 121, 4443-4448.	1.4	56
226	Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood, 2013, 122, 1144-1149.	1.4	146
227	A Clinical Prognostic Model for the Identification of Low-Risk Patients With Acute Symptomatic Pulmonary Embolism and Active Cancer. Chest, 2013, 143, 138-145.	0.8	58
228	Age-Adjusted D-Dimer Cut-off Levels to Rule out Pulmonary Embolism: A Prospective Outcome Study. Blood, 2013, 122, LBA-4-LBA-4.	1.4	0
229	Deep Venous Thrombosis and Pulmonary Embolism. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 125-126.	2.1	2
230	The Diagnostic Management of Recurrent Deep Vein Thrombosis and Pulmonary Embolism. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 151-155.	2.1	3
231	The combination of four different clinical decision rules and an age-adjusted D-dimer cut-off increases the number of patients in whom acute pulmonary embolism can safely be excluded. Thrombosis and Haemostasis, 2012, 107, 167-171.	3.4	32
232	Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thrombosis and Haemostasis, 2012, 107, 838-847.	3.4	201
233	Accuracy of Magnetic Resonance Direct Thrombus Imaging (MRDTI) As a Novel Tool in the Diagnosis of Acute Ipsilateral Recurrent Deep Vein Thrombosis. Blood, 2012, 120, 395-395.	1.4	6
234	Recovery of right and left ventricular function after acute pulmonary embolism. Clinical Radiology, 2011, 66, 1203-1207.	1.1	7

#	Article	IF	CITATIONS
235	A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thrombosis Research, 2011, 128, 21-26.	1.7	76
236	Computed tomography pulmonary angiography as a single imaging test to rule out pulmonary embolism. Current Opinion in Pulmonary Medicine, 2011, 17, 380-386.	2.6	24
237	Performance of 4 Clinical Decision Rules in the Diagnostic Management of Acute Pulmonary Embolism. Annals of Internal Medicine, 2011, 154, 709.	3.9	211
238	Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review. British Journal of Haematology, 2011, 153, 168-178.	2.5	85
239	The proof for new oral anticoagulants: clinical trial evidence. European Orthopaedics and Traumatology, 2011, 2, 7-14.	0.1	3
240	Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. Internal and Emergency Medicine, 2011, 6, 521-528.	2.0	56
241	Pulmonary flow profile and distensibility following acute pulmonary embolism. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 14.	3.3	9
242	Reply to C.L. O'Connell et al. Journal of Clinical Oncology, 2011, 29, 4209-4210.	1.6	3
243	Measurement of Right and Left Ventricular Function by ECG-Synchronized CT Scanning in Patients With Acute Pulmonary Embolism. Chest, 2011, 140, 1008-1015.	0.8	50
244	Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 652-660.	2.2	76
245	Quality of Life in Long-term Survivors of Acute Pulmonary Embolism. Chest, 2010, 138, 1432-1440.	0.8	136
246	Patient Outcomes after Acute Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 501-506.	5.6	138
247	Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica, 2010, 95, 970-975.	3.5	220
248	Safety of excluding acute pulmonary embolism based on an unlikely clinical probability by the Wells rule and normal D-dimer concentration: A meta-analysis. Thrombosis Research, 2010, 125, e123-e127.	1.7	77
249	Is pulmonary embolism associated with reactive mediastinal and hilar lymphadenopathy?. Thrombosis Research, 2010, 125, 557-558.	1.7	2
250	Prevalence and potential determinants of exertional dyspnea after acute pulmonary embolism. Respiratory Medicine, 2010, 104, 1744-1749.	2.9	92
251	Outpatient Treatment In Patients with Acute Pulmonary Embolism: The Hestia Study. Blood, 2010, 116, LBA-1-LBA-1.	1.4	0
252	Diagnostic management of clinically suspected acute pulmonary embolism. Journal of Thrombosis and Haemostasis, 2009, 7, 312-317.	3.8	44

#	Article	IF	CITATIONS
253	D-dimer Testing in Patients with Suspected Pulmonary Embolism and Impaired Renal Function. American Journal of Medicine, 2009, 122, 1050-1053.	1.5	52
254	Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty. New England Journal of Medicine, 2008, 358, 2765-2775.	27.0	1,349
255	Simplification of the Revised Geneva Score for Assessing Clinical Probability of Pulmonary Embolism. Archives of Internal Medicine, 2008, 168, 2131.	3.8	255
256	The physician's estimation â€~alternative diagnosis is less likely than pulmonary embolism' in the Wells rule is dependent on the presence of other required items. Thrombosis and Haemostasis, 2008, 99, 244-245.	3.4	16
257	Clinically suspected acute recurrent pulmonary embolism: A diagnostic challenge. Thrombosis and Haemostasis, 2007, 97, 944-948.	3.4	18
258	Simple and safe exclusion of pulmonary embolism in outpatients using quantitative D-dimer and Wells' simplified decision rule. Thrombosis and Haemostasis, 2007, 97, 146-150.	3.4	51
259	Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial Blood, 2007, 110, 6-6.	1.4	12
260	Resolution of Thromboemboli in Patients With Acute Pulmonary Embolism. Chest, 2006, 129, 192-197.	0.8	215
261	Effectiveness of Managing Suspected Pulmonary Embolism Using an Algorithm Combining Clinical Probability, D-Dimer Testing, and Computed Tomography. JAMA - Journal of the American Medical Association, 2006, 295, 172.	7.4	935
262	Macrophage Low-Density Lipoprotein Receptor-Related Protein Deficiency Enhances Atherosclerosis in ApoE/LDLR Double Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2710-2715.	2.4	61
263	Treating Patients with Venous Thromboembolism: Initial Strategies and Long-Term Secondary Prevention. Seminars in Vascular Medicine, 2005, 5, 276-284.	2.1	15
264	Right Ventricular Dysfunction and Pulmonary Obstruction Index at Helical CT: Prediction of Clinical Outcome during 3-month Follow-up in Patients with Acute Pulmonary Embolism. Radiology, 2005, 235, 798-803.	7.3	453
265	Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor Blood, 2005, 106, 280-280.	1.4	7
266	Treatment of venous thromboembolism: duration and new options. The Hematology Journal, 2004, 5, S24-S28.	1.4	2
267	Arterial indications for the low molecular weight heparins. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 233.	1.5	1
268	Recurrent venous thromboembolism: diagnosis and management. Current Opinion in Pulmonary Medicine, 2000, 6, 330-334.	2.6	15
269	Partial protein S gene deletion in a family with hereditary thrombophilia. Blood, 1989, 73, 479-483.	1.4	55
270	Unexpected High Prevalence of Silent Pulmonary Embolism in Patients with Deep Venous Thrombosis. Chest, 1989, 95, 498-502.	0.8	335

#	Article	IF	CITATIONS
271	Partial protein S gene deletion in a family with hereditary thrombophilia. Blood, 1989, 73, 479-483.	1.4	3
272	Prevalence, risk factors, and long-term outcomes of cerebral ischemia in hospitalized COVID-19 patients – study rationale and protocol of the CORONIS study: A multicentre prospective cohort study. European Stroke Journal, 0, , 239698732210925.	5.5	2